Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

15.22
+0.47003.19%
Post-market: 15.05-0.1700-1.12%19:54 EDT
Volume:3.88M
Turnover:58.72M
Market Cap:1.50B
PE:-2.61
High:15.28
Open:14.90
Low:14.67
Close:14.75
52wk High:39.89
52wk Low:12.73
Shares:98.32M
Float Shares:80.72M
Volume Ratio:0.82
T/O Rate:4.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8279
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-24.22%
PB:-5.14
PE(LYR):-2.61

Loading ...

How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) Q2 Revenue Gain And Narrower Net Loss

Simply Wall St.
·
Aug 10

Analysts Have Conflicting Sentiments on These Healthcare Companies: Stevanato Group (STVN), Ultragenyx Pharmaceutical (RARE) and PROCEPT BioRobotics (PRCT)

TIPRANKS
·
Aug 06

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Ultragenyx Pharmaceutical (RARE) and Beam Therapeutics (BEAM)

TIPRANKS
·
Aug 05

Ultragenyx price target raised to $81 from $79 at Canaccord

TIPRANKS
·
Aug 05

Ultragenyx Pharmaceutical Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Earnings Flash (RARE) Ultragenyx Pharmaceutical Posts Q2 Loss of $0.90 per Share, vs. FactSet Est $1.22 Loss

MT Newswires Live
·
Aug 05

Ultragenyx Q2 Revenue Rises 28% to Record High, Net Loss Narrows

Reuters
·
Aug 05

Ultragenyx Pharmaceutical Q2 EPS $(0.90) Beats $(1.51) Estimate, Sales $214.000M Beat $158.777M Estimate

Benzinga Earnings
·
Aug 05

Ultragenyx Q2 EPS USD -0.9

Reuters
·
Aug 05

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

GlobeNewswire
·
Aug 05

Ultragenyx EVP, Chief Legal Officer Karah Parschauer Disposes of 1,900 Common Shares for $47,348‬

Reuters
·
Aug 05

Ultragenyx Pharma is Maintained at Buy by Guggenheim

Dow Jones
·
Aug 04

Ultragenyx price target lowered to $35 from $43 at Guggenheim

TIPRANKS
·
Aug 04

Ultragenyx Grants 65,886 Restricted Stock Units to 39 New Hires Under Inducement Plan

Reuters
·
Jul 25

Ultragenyx Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 25

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 25

Goldman Sachs Sticks to Its Hold Rating for Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Jul 22

Ultragenyx Pharmaceutical Currently Down Eight Consecutive Days, on Pace for Longest Losing Streak Since December 2024

Dow Jones
·
Jul 18

Wedbush Releases a Hold Rating on Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Jul 13

Wedbush Raises Price Target on Ultragenyx Pharmaceutical to $30 From $26, Keeps Neutral Rating

MT Newswires Live
·
Jul 13